Mr. Henry Dubina reeports

TELESCOPE INNOVATIONS PROVIDES FINANCIAL RESULTS OF SECOND FISCAL QUARTER 2026

Telescope Innovations Corp. has released its financial results for the fiscal quarter ended Feb. 28, 2026 (Q2 (second quarter) FY (fiscal year) 2026). The company generated revenues of approximately $1.6-million during this period, with strong contributions from the development and delivery of self-driving laboratories (SDL), with an adjusted EBITA (earnings before interest, taxes and amortization) loss of $710,000, consistent with management's expectations. Year-to-date gross revenues increased to $4.3-million, compared with $2.2-million in the same six-month period last year.

Financial highlights of the fiscal quarter ended february 28, 2026 (Q2 FY 2026):

• Revenues of $1.64-million (versus $1.00-million in Q2 FY 2025);
• Expenses of $3.11-million (versus $1.72-million in Q2 FY 2025);
• Adjusted EBITA loss of $710,000 (versus a loss of $440,000 in Q2 FY 2025);
• Expenses and investments continued to support company growth in the second fiscal quarter. Expense increases were associated with:
  • Consulting and salary costs incurred with hiring of technical, sales and research to support rapid growth in the business;
  • Parts expenses and travel expenses related to product sales, product fulfilment (installation and training) and general sales activity.

Operational highlights:

• Self-driving labs (SDLs):
  • Telescope's SDL inauguration at the Korean Pharmaceutical and Biopharma Biopharma Manufacturer's Association was supported by two-time Nobel Prize Laureate Dr. Barry Sharpless, as well as the Acceleration Consortium and Global Affairs Canada. This achievement underscores the technical excellence of Telescope's SDL platforms, as well as the accelerating commercial momentum and international collaboration.
  • Quarterly revenue was driven strongly by the delivery of the second self driving laboratory to Pfizer.
• Lithium processing portfolio:
  • The company has secured additional laboratory space adjacent to its primary labs at the University of British Columbia. The strategic location hosts dedicated infrastructure for continued process development of its lithium carbonate (ReCRFT) and lithium sulphide (DualPure) production and purification technologies.
  • The company's ReCRFT process has produced battery-grade lithium carbonate from battery recycling streams. Its collaboration partner has successfully integrated this recycled material into a functional battery cell, confirming the viability of ReCRFT for battery recycling applications.
  • The DualPure program for low-temperature lithium sulphide production continues to advance in partnership with Standard Lithium Ltd., and Telescope is currently engaged in advanced technical discussions with several Asian and North American industry leaders in the solid-state battery sector.

"Telescope has enjoyed tangible progress this quarter as we scale both our technology and our business," said Henry Dubina, Telescope chief executive officer. "Delivering our second self-driving laboratory to Pfizer, expanding internationally, demonstrating lithium battery recycling through our ReCRFT process, and expanding our lab infrastructure to grow the lithium portfolio all demonstrate technical proof and strong market demand across our platforms. These milestones position the company to continue delivering technical and commercial targets throughout the fiscal year."

Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the quarter ended Feb. 28, 2026, both of which are available under the profile for the company on SEDAR+.

About Telescope Innovations Corp.

Telescope is a chemical technology company developing intelligent automation technologies and scalable manufacturing processes for the pharmaceutical and chemical industry. The company builds and deploys reaction sampling systems for real-time analysis, flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency and data quality. The company's self-driving labs are fully autonomous, physical AI (artificial intelligence) platforms that plan, execute and analyze experiments far more efficiently than traditional manual approaches. Biopharmaceutical, high-value specialty chemical and advanced materials companies utilize Telescope's products and services to accelerate the development and optimization of chemical processes, thereby cutting down time and costs from lab to market.

We seek Safe Harbor.